Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH

PartnershippositivePositive

AI Analysis

Summary

Suzhou Ribo Life Science and Madrigal Pharmaceuticals announced achievement of a first important milestone in the development of new siRNA therapies for MASH through their collaboration.

Outcome Details

Ribo and Madrigal achieved a first important milestone in advancing new siRNA therapies for MASH

Importance:6/10

Sentiment:

0.60

siRNAMASHPartnershipCollaborationMilestone

Related Companies

$06938.HK $MDGL

Read the original article

Published by PR Newswire Clinical Trials on July 2, 2026 6:27 AM

Read Original